How have GNFTF shares performed in 2024?

Genfit's stock was trading at $3.45 on January 1st, 2024. Since then, GNFTF stock has decreased by 14.5% and is now trading at $2.95. View the best growth stocks for 2024 here .

How do I buy shares of Genfit?

Shares of GNFTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:GNFTF

Genfit (GNFTF) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free GNFTF Stock Alerts

$2.95

-0.03 (-1.01%)

(As of 04/15/2024 ET)

Compare

Today's Range: $2.95
▼
$2.95
50-Day Range: $2.98
▼
$3.45
52-Week Range: $2.98
▼
$3.45

Volume: 150 shs
Average Volume: 1,225 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Headlines Short Interest

Get Genfit alerts:

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About Genfit Stock (OTCMKTS:GNFTF)

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

GNFTF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GNFTF Stock News Headlines

March 8, 2024 | msn.com

Inventiva resumes Phase 3 study for NASH drug, stock up 6%

December 11, 2023 | markets.businessinsider.com

Optimistic Outlook for Genfit: Justine Telliez Raises Target Price Amid Positive Drug Developments

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

December 9, 2023 | markets.businessinsider.com

Buy Rating Affirmed for Genfit SA on Strong Elafibranor Efficacy and Favorable Regulatory Prospects

December 8, 2023 | markets.businessinsider.com

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

November 15, 2023 | lse.co.uk

Genfit Share Price (GNFT.PA)

November 14, 2023 | marketwatch.com

Ipsen, Genfit Drug Fights Liver Disease Progression, Phase-Three Trial Finds

November 12, 2023 | seekingalpha.com

Genfit reports 9M results

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

September 23, 2023 | markets.businessinsider.com

Kepler Capital Sticks to Their Buy Rating for Genfit (GNFTF)

July 4, 2023 | markets.businessinsider.com

SVB Securities Remains a Buy on Genfit SA (GNFT)

June 30, 2023 | marketwatch.com

Genfit Shares Jump 27% After Positive Phase 3 Trial Results

June 30, 2023 | msn.com

U.S.-listed shares of Genfit soar 24% after positive results from late-stage trial of treatment for rare type of liver disease

June 7, 2023 | markets.businessinsider.com

Genfit Gears Up For Primary Biliary Cholangitis Trial Data

June 3, 2023 | markets.businessinsider.com

Genfit (GNFTF) Receives a Buy from Kepler Capital

April 21, 2023 | msn.com

ODDO BHF Maintains Genfit (EPA:GNFT) Buy Recommendation

April 21, 2023 | msn.com

SVB SECURITIES Maintains Genfit (EPA:GNFT) Outperform Recommendation

January 24, 2023 | benzinga.com

GENFIT Announces 2023 Financial Calendar

November 23, 2022 | seekingalpha.com

A Long Wait For Genfit May Be Worth It

September 29, 2022 | nz.finance.yahoo.com

GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis

September 19, 2022 | finance.yahoo.com

GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases

September 14, 2022 | thestreet.com

Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study

September 13, 2022 | finance.yahoo.com

FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma

September 12, 2022 | thestreet.com

Genfit's French Fans Fume Following Failure of Fatty Liver Drug

September 9, 2022 | finance.yahoo.com

Genfit S.A. (GNFT)

August 20, 2022 | reuters.com

GNFT.OQ - Genfit SA (ADR) | Stock Price & Latest News | Reuters

August 19, 2022 | msn.com

Analyzing Genfit's Short Interest

See More Headlines

Receive GNFTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:GNFTF
CUSIP: N/A
CIK: N/A
Web: www.genfit.com
Phone: (332) 016-4000
Fax: N/A
Employees: 154
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Jean-Francois Mouney (Age 69)
Co-Founder & Chairman of the Board
Comp: $400.24k
Mr. M. Pascal Prigent (Age 56)
Chief Executive Officer
Comp: $606.58k
Prof. Bart Staels (Age 61)
Co-Founder & Chairman of the Scientific Advisory Board
Mr. Thomas Baetz (Age 50)
Chief Financial Officer
Mr. Pascal Caisey (Age 56)
Chief Operating Officer
Dr. Meriam Kabbaj Ph.D. (Age 50)
Chief Technology Officer
Dr. Dean W. Hum Ph.D. (Age 62)
Chief Scientific Officer
Comp: $771.84k
Mr. Jean-Christophe Marcoux (Age 46)
Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG
Mr. Laurent Lannoo (Age 54)
Corporate Secretary & Director of Legal Affairs
Ms. Stefanie Magner J.D. (Age 43)
Chief Compliance Officer & Executive VP of International Legal Affairs

Key Competitors

View All Competitors

GNFTF Stock Analysis - Frequently Asked Questions

How have GNFTF shares performed in 2024?: Genfit's stock was trading at $3.45 on January 1st, 2024. Since then, GNFTF stock has decreased by 14.5% and is now trading at $2.95.
View the best growth stocks for 2024 here.
How do I buy shares of Genfit?: Shares of GNFTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:GNFTF) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial